United States Patent 8,404,702: Rolapitant Hydrochloride Monohydrate Claims, Scope, Expiration and Patent Landscape

U.S. Patent No. 8,404,702 covers treatment methods using a crystalline salt of rolapitant, principally rolapitant hydrochloride monohydrate, an oral neurokinin-1 receptor antagonist marketed as VARUBI. The patent does not broadly claim rolapitant as a chemical entity. Its commercial significance is concentrated in crystalline-salt use, oral dosage forms, specified strengths, chemotherapy-induced nausea and vomiting treatment, combination antiemetic therapy, and selected pharmacokinetic parameters.

The strongest practical protection is concentrated in claims 12, 15, 16, 19, 21, 23 and 24. Those claims converge on an oral tablet or capsule containing 5 to 200 mg, particularly a 200 mg tablet, of crystalline rolapitant hydrochloride monohydrate.

What drug and active ingredient does U.S. Patent 8,404,702 protect?

The claimed compound is rolapitant, chemically identified as:

(5S,8S)-8-{[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl}-8-phenyl-1,7-diazaspiro[4.5]decan-2-one.

The patent focuses on a crystalline salt of rolapitant rather than the free base. The principal claimed solid form is the hydrochloride monohydrate.

Element	Patent relevance
Active ingredient	Rolapitant
Primary salt	Hydrochloride
Primary solid form	Crystalline hydrochloride monohydrate
Primary route	Oral
Dosage range	5 to 200 mg per dosage form
Key marketed strength	200 mg
Main indication	Acute nausea and emesis, including chemotherapy-induced nausea and vomiting
Product association	VARUBI, rolapitant hydrochloride
Regulatory pathway	Small-molecule NDA, not a biologic

Rolapitant is an NK1 receptor antagonist. The patent claims are directed to therapeutic administration and dosage-form characteristics rather than receptor binding, molecular mechanism, or a new chemical entity.

What are the independent claims in U.S. Patent 8,404,702?

The patent has four principal independent method claims.

Claim 1: broad crystalline-salt treatment claim

Claim 1 covers:

Treatment of acute-onset nausea and/or emesis;
In a mammal;
By administering a pharmaceutical formulation;
Containing a crystalline salt of rolapitant; and
Containing a pharmaceutically acceptable excipient.

The claim does not expressly limit the indication to chemotherapy. Claim 2 adds chemotherapy, radiation therapy and post-operative nausea or emesis.

The term “crystalline salt” is broader than “crystalline hydrochloride monohydrate.” Claim 1 can therefore encompass crystalline salts other than the hydrochloride, provided that the salt and the remaining claim elements are met. Claims 11 and 12 narrow the salt to hydrochloride and hydrochloride monohydrate.

Claim 5: chemotherapy combination claim

Claim 5 requires administration of:

A pharmaceutical formulation containing a crystalline rolapitant salt; and
A chemotherapeutic agent.

The combination must treat acute-onset nausea and/or emesis associated with chemotherapy.

Claims 6 through 10 define the timing relationship. The rolapitant formulation may be administered:

Simultaneously with chemotherapy;
Before chemotherapy;
During chemotherapy; or
After chemotherapy.

The timing language creates multiple infringement pathways. A defendant does not avoid the dependent claims merely because rolapitant is not administered at exactly the same time as the chemotherapeutic agent, provided the administration falls within the stated contemporaneous sequence.

Claim 17: three-component antiemetic regimen

Claim 17 requires:

Crystalline rolapitant hydrochloride monohydrate;
A corticosteroid and/or a 5-HT3 receptor antagonist; and
A chemotherapeutic agent.

Claim 18 identifies dexamethasone and the 5-HT3 antagonists ondansetron, granisetron, palonosetron, dolasetron and tropisetron.

This claim is narrower than claim 5 but commercially important because chemotherapy-induced nausea and vomiting regimens commonly use an NK1 antagonist with dexamethasone and a serotonin 5-HT3 antagonist.

Claim 21: oral dosage-form claim

Claim 21 covers treatment using an oral dosage form containing 5 to 200 mg of crystalline rolapitant hydrochloride monohydrate.

Claims 22 and 23 limit the dosage form to a capsule or tablet, and then to a tablet. Claim 24 specifically requires a 200 mg tablet.

How do the dependent claims narrow the patent’s scope?

The claim set progressively narrows from a crystalline salt to a specific solid form, formulation, strength and dosage form.

Claims	Limiting subject matter	Commercial significance
1-4	Crystalline rolapitant salt, excipient, oral dosage form and indications	Broad treatment coverage
5-10	Crystalline salt plus chemotherapy, with specified timing	Combination-use protection
11-12	Hydrochloride, then hydrochloride monohydrate	Key solid-form limitation
13-14	Named excipients and granular formulation	Formulation-process coverage
15-16	5-200 mg, including 200 mg	Strength-specific protection
17-20	Hydrochloride monohydrate plus corticosteroid and/or 5-HT3 antagonist, with PK parameters	Regimen and pharmacokinetic coverage
21-24	Oral dosage form, tablet or capsule, particularly 200 mg tablet	Product-facing protection

Claim 13 identifies lactose, microcrystalline cellulose, croscarmellose sodium, pregelatinized starch and magnesium stearate. Those excipients are conventional oral-tablet ingredients. Their presence may make the claim easier to read on a commercial tablet but generally limits the claim to formulations containing at least one listed excipient.

Claim 14 covers a granular formulation. A generic product using a different manufacturing process could potentially avoid claim 14 while still implicating claims 1, 12, 21 or 24.

What formulations are protected by U.S. Patent 8,404,702?

The patent protects treatment methods using formulations that contain crystalline rolapitant salt. The narrowest commercially relevant formulation is a 200 mg oral tablet containing crystalline rolapitant hydrochloride monohydrate.

Potentially covered formulations include:

Immediate-release tablets;
Capsules;
Granular oral formulations;
Dosage forms containing 5, 10, 25, 50, 100 or 200 mg;
Formulations containing the listed excipients;
Formulations used alone or in chemotherapy combination regimens.

The claims do not expressly require a particular dissolution profile, particle-size distribution, tablet hardness, coating, release mechanism or manufacturing process. A formulation that uses a different excipient system may still fall within the broader claims if it contains the required crystalline salt and is administered for the claimed treatment.

The patent also does not appear, from the supplied claims, to require a particular polymorph designation beyond crystallinity and, in the narrower claims, the hydrochloride monohydrate form. Solid-state characterization would therefore be central in any infringement or validity dispute.

How strong is the patent estate for rolapitant?

U.S. Patent 8,404,702 is strongest as a product-use and formulation patent. It is materially narrower than a composition-of-matter patent claiming rolapitant itself.

Strengths

It identifies the commercially relevant hydrochloride monohydrate form.
It covers the principal oral administration route.
It includes the marketed 200 mg strength.
It covers chemotherapy-induced nausea and vomiting.
It reaches common combination regimens using dexamethasone and 5-HT3 antagonists.
It includes both broad treatment claims and narrower tablet-specific claims.
It can implicate an ANDA applicant that proposes the same salt, dosage form, strength and labeled indication.

Weaknesses

The independent claims are method claims rather than composition claims.
Claims 1 and 5 require treatment or administration, creating divided-infringement issues where multiple entities participate in prescribing, dispensing and administration.
“Crystalline salt” may raise claim-construction and written-description issues if the specification does not adequately support salts beyond the hydrochloride monohydrate.
Conventional excipient limitations may be vulnerable if they do not materially distinguish the formulation.
The PK limitation in claim 20 may create enablement, indefiniteness or reproducibility disputes.
A generic sponsor may attempt a section viii carve-out for nonprotected indications, subject to the scope of the Orange Book-listed use codes and the proposed label.

The patent’s practical value therefore depends on three variables: whether it is listed for the reference product, whether the generic label includes the claimed indication, and whether the generic formulation uses the claimed crystalline salt.

When does U.S. Patent 8,404,702 lose exclusivity?

The patent issued on April 2, 2013. Its effective expiration depends on the earliest applicable nonprovisional filing date, patent-term adjustment and any terminal disclaimer. The ordinary 20-year patent term is calculated from the relevant U.S. nonprovisional or international filing date, not from the issue date (35 U.S.C. § 154).

Public patent-family records associate the patent family with a June 2008 priority date and a 2029-era U.S. patent-term endpoint. The precise enforceable expiration date should be taken from the USPTO patent record, including any patent-term adjustment or terminal-disclaimer information. The issue date alone does not establish the expiration date.

Regulatory exclusivity

Rolapitant received FDA approval for VARUBI in 2015. New chemical entity exclusivity, if awarded with the original NDA, would generally provide five years from approval, subject to the statutory rules governing abbreviated applications and paragraph IV certifications. That regulatory exclusivity period is separate from the patent term and would not extend the patent.

The relevant regulatory framework includes:

Five-year new chemical entity exclusivity;
Three-year exclusivity for certain approved changes supported by clinical investigations;
ANDA paragraph IV certification procedures;
Section viii statements for indications not covered by listed method-of-use patents.

FDA approval of the reference product does not establish that every patent in the family is listed in the Orange Book. Listing depends on FDA’s patent-submission determination and the statutory listing rules.

What is the Orange Book status of VARUBI and rolapitant?

VARUBI was approved under NDA 208614 for prevention of delayed chemotherapy-induced nausea and vomiting in adults receiving highly emetogenic or moderately emetogenic cancer chemotherapy. The product contains rolapitant hydrochloride and is supplied as an oral tablet.

The Orange Book analysis should separate four categories:

Category	Relevance
Active ingredient patent	Protects rolapitant itself, if listed and unexpired
Solid-form patent	Protects a crystalline salt or hydrate
Formulation patent	Protects a dosage form or excipient composition
Method-of-use patent	Protects chemotherapy-related nausea and vomiting treatment

U.S. Patent 8,404,702 is most naturally analyzed as a formulation and method-of-use patent. Its claims include product-specific limitations, but they are drafted as methods of treatment. That distinction matters for Orange Book listing, ANDA certification and litigation strategy.

An ANDA applicant addressing an Orange Book-listed patent would generally select one of four certifications:

Paragraph I: no patent information is listed;
Paragraph II: the listed patent has expired;
Paragraph III: approval is sought after patent expiration; or
Paragraph IV: the patent is invalid, unenforceable or will not be infringed.

A section viii statement may be available for a carve-out indication, but it does not remove the risk created by a generic label that instructs use for the patented chemotherapy regimen.

Which companies could challenge rolapitant patent protection?

Generic-drug companies, not biosimilar sponsors, would be the relevant challengers. Rolapitant is a chemically synthesized small molecule, so the competitive pathway is an ANDA rather than a biosimilar application under the Public Health Service Act.

Potential challenger categories include:

Large generic manufacturers filing ANDAs;
Specialty generic companies targeting oncology-supportive-care products;
Contract manufacturers supporting an ANDA sponsor;
Paragraph IV litigants seeking early market entry.

The supplied patent claims do not identify any settled paragraph IV challenge, license or litigation outcome. A complete company-by-company challenge list cannot be established from the claim text alone.

What patent litigation affects U.S. Patent 8,404,702?

The primary litigation risk would arise after an ANDA applicant sends a paragraph IV notice alleging that the patent is invalid, unenforceable or not infringed. The patent holder could then file an action under 35 U.S.C. § 271(e)(2), potentially triggering the statutory 30-month stay of FDA approval, subject to the governing procedural conditions.

Likely litigation issues would include:

Whether the ANDA product contains crystalline rolapitant hydrochloride monohydrate;
Whether the generic label induces treatment of chemotherapy-induced nausea and vomiting;
Whether the proposed 200 mg tablet falls within claims 21-24;
Whether the generic’s combination-use instructions implicate claims 5-10 or 17-19;
Whether the claimed crystalline form is anticipated or obvious;
Whether the claims adequately describe and enable the full claimed salt scope;
Whether the PK limitations are definite and reproducible;
Whether the patent was properly listed for the reference product.

A generic that uses the same active ingredient but a different salt, amorphous form or formulation may have a stronger noninfringement position. That position weakens if solid-state testing demonstrates conversion to, or inclusion of, the patented hydrochloride monohydrate.

What generic launch scenarios exist for rolapitant?

Scenario 1: Same hydrochloride monohydrate and same indication

This is the highest-risk scenario. A generic using the same crystalline hydrochloride monohydrate in a 200 mg oral tablet and carrying the chemotherapy-induced nausea and vomiting indication would face the strongest infringement case under claims 12, 21, 23 and 24.

Scenario 2: Same active ingredient, different solid form

An amorphous rolapitant formulation or a different salt could avoid claims limited to crystalline hydrochloride monohydrate. The sponsor would still need to assess broader claims covering a crystalline salt and any separate composition-of-matter or use patents.

Scenario 3: Section viii indication carve-out

A generic could attempt to omit a patented indication from its labeling. This strategy is less useful where the remaining label, dosing instructions or promotional materials still direct use for chemotherapy-induced nausea and vomiting.

Scenario 4: Post-expiration launch

A paragraph III certification can defer approval until the relevant patent expires. This is the lowest litigation-risk pathway but delays commercial entry.

How does this patent compare with a compound patent?

Issue	U.S. Patent 8,404,702	Compound patent
Claim type	Method of treatment and formulation use	Chemical composition
Protected subject	Crystalline rolapitant salt and clinical use	Rolapitant molecule
Design-around potential	Moderate to high	Low
Solid-form testing importance	High	Moderate
Label dependence	High	Lower
ANDA litigation risk	Strong if label and formulation match	Strong across most uses
Commercial protection	Product-specific and indication-specific	Broad market protection

The patent is commercially meaningful but should not be treated as equivalent to a basic compound patent. Its enforceability depends heavily on the generic’s formulation and proposed label.

Does rolapitant face biosimilar risk?

No conventional biosimilar pathway applies. Rolapitant is a small-molecule drug, and competitive entry would normally proceed through an ANDA or, for a materially different product, a full NDA.

The relevant risks are generic substitution, paragraph IV litigation, salt or polymorph design-around, and label carve-outs. Manufacturing barriers may still arise from control of the crystalline form, reproducible hydration state, particle size, stability and analytical characterization.

Key Takeaways

U.S. Patent 8,404,702 protects methods using crystalline rolapitant salts, with its most commercially important claims directed to crystalline rolapitant hydrochloride monohydrate.
The patent covers chemotherapy-induced nausea and vomiting, oral dosage forms, 5 to 200 mg strengths and a specific 200 mg tablet.
Claims 5-10 and 17-20 extend protection to chemotherapy combinations, administration timing and selected pharmacokinetic parameters.
The patent is narrower than a composition-of-matter patent and is more vulnerable to salt, solid-form, formulation and labeling design-arounds.
A generic using the same hydrochloride monohydrate, 200 mg tablet and chemotherapy indication would face the highest infringement exposure.
Rolapitant is a small molecule, so generic ANDA and paragraph IV risks apply; biosimilar competition does not.
The patent has a 2029-era term endpoint based on public family information, but the enforceable date depends on the USPTO record, patent-term adjustment and any terminal disclaimer.
FDA Orange Book analysis must distinguish listed method-of-use patents from unlisted formulation or solid-form rights.

FAQs

Is U.S. Patent 8,404,702 a patent on rolapitant itself?

No. The supplied claims are method claims requiring administration of a formulation containing a crystalline rolapitant salt. They do not broadly claim every form or use of the rolapitant molecule.

Does the patent cover a 200 mg VARUBI tablet?

Yes, claim 24 specifically addresses a tablet containing 200 mg of crystalline rolapitant hydrochloride monohydrate, subject to the claim’s remaining limitations.

Can a generic avoid the patent by using rolapitant free base?

Potentially. Claims 11, 12, 19 and 21-24 require the hydrochloride or hydrochloride monohydrate. A free-base product would need separate analysis under the broader crystalline-salt claims and any other rolapitant patents.

Does administering rolapitant after chemotherapy avoid the patent?

No. Claim 10 expressly covers administration after administration of the chemotherapeutic agent when the timing is contemporaneous as defined by the claim.

What is the main invalidity risk for this patent?

The principal risks are anticipation or obviousness of the crystalline salt and treatment regimen, inadequate written description for the salt scope, enablement of the claimed solid forms and PK range, and indefiniteness in the PK limitation.

References

Food and Drug Administration. (2015). VARUBI (rolapitant hydrochloride) prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,404,702, methods of treatment using crystalline rolapitant salts. U.S. Department of Commerce.
United States Code. (2023). 35 U.S.C. §§ 154, 271(e)(2).
United States Code. (2023). 21 U.S.C. §§ 355(j), 355a.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tersera	VARUBI	rolapitant hydrochloride	EMULSION;INTRAVENOUS	208399-001	Oct 25, 2017		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY	⤷ Start Trial
Tersera	VARUBI	rolapitant hydrochloride	TABLET;ORAL	206500-001	Sep 1, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	060303	⤷ Start Trial
Australia	2007233389	⤷ Start Trial
Brazil	PI0710577	⤷ Start Trial
Canada	2648640	⤷ Start Trial
Canada	2861281	⤷ Start Trial
Chile	2007000945	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,404,702

Which drugs does patent 8,404,702 protect, and when does it expire?

Summary for Patent: 8,404,702